Una reducción importante en la administración de líquidos intravenosos durante surgeries across nine Bronx hospitals between September 2 and December 31, 2024, did not increase rates of acute kidney injury or intraoperative hypotension, according to a study published on September 15, 2026, in JAMA Network Open. Triggered by a national IV fluid shortage, the health system implemented a 12-step conservation strategy that cut weekly crystalloid distribution to operating rooms by a significant margin without worsening patient clinical outcomes or raising overall hospital care costs.
How the IV Fluid Shortage Sparked a Surgical Shift
The nationwide supply chain disruption forced hospital administrators to rethink routine fluid management. To stretch dwindling supplies, the network adopted strict conservation measures, including using smaller fluid bags and reducing the physical stock of solutions inside operating suites. These changes took effect on October 9, 2024, creating what researchers described as a rare natural experiment.
Historically, clinicians balance hemodynamic stability against the risks of fluid overload. While excessive intravenous fluids can lead to postoperative complications, overly restrictive strategies can impair kidney function and cause dangerous drops in blood pressure. The study evaluated 38,976 patients undergoing procedures—including 12,026 treated before the intervention and 26,950 treated during it—to see what happened when operating rooms drastically curtailed crystalloid use.
Clinical Outcomes and Fluid Volume Reductions
After adjusting for patient age, sex, body mass index, surgical duration, and comorbidities, researchers recorded a significant drop in intraoperative crystalloid administration. Weekly fluid volumes delivered to the operating rooms fell from an average of 1,793 liters down to 1,118 liters.
Despite this massive drop, the adjusted relative risk for acute kidney injury was 0.97, showing no statistically significant difference between the two periods. Furthermore, the strategy did not increase intraoperative hypotension, major adverse cardiovascular events, or postoperative respiratory complications. Average intraoperative urine output dropped by 27 milliliters, and urinary catheter use during procedures fell from 10.9% before the strategy to 9.2% during its implementation, reflecting a statistically significant adjusted relative risk of 0.87.
Hospital Readmissions and Cost Impacts
Unexpectedly, the proportion of patients readmitted within 30 days dropped from 6.3% before the intervention to 5.1% during implementation, yielding an adjusted relative risk of 0.82. However, study authors cautioned that the observational design cannot prove that restricted fluid use directly caused the drop in readmissions, as the study did not track specific diagnoses or preventable readmission factors.
Financially, weekly wholesale costs for crystalloids surged more than tenfold during the shortage, generating additional expenses over a 12-week window. Despite this spike in raw material costs, total overall hospital care costs remained statistically unchanged between the pre-intervention and intervention groups.
Next Steps and Clinical Limitations
Because the investigation relied on a retrospective cohort from a single urban hospital network in New York, the findings cannot automatically be generalized to rural facilities or entirely different healthcare systems. The study authors emphasize that their data does not endorse a universal fluid restriction for every patient or procedure. Robust randomized clinical trials remain necessary to define optimal fluid volumes and validate individualized hemodynamic management.
Keep reading